S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation (Ad)
Applied Materials stock is Ray Dalio's favorite in this new cycle
Palo Alto Networks aims at cyber security leadership
Critical asset just had biggest fall on record (Ad)
Spotify sounding better to analysts as company tunes into profits
3 Reasons the Capital One-Discover merger is a big deal
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Bears covered shorts on this ETF, 3 stocks to pop on the shift

OvaScience (OVAS) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

OVAS vs. IMAB, NGM, MCRB, RENB, GBIO, VTGN, ATOS, ORMP, NKTR, and KPTI

Should you be buying OvaScience stock or one of its competitors? The main competitors of OvaScience include I-Mab (IMAB), NGM Biopharmaceuticals (NGM), Seres Therapeutics (MCRB), Renovaro Biosciences (RENB), Generation Bio (GBIO), Vistagen Therapeutics (VTGN), Atossa Therapeutics (ATOS), Oramed Pharmaceuticals (ORMP), Nektar Therapeutics (NKTR), and Karyopharm Therapeutics (KPTI). These companies are all part of the "medical" sector.

OvaScience vs.

OvaScience (NASDAQ:OVAS) and I-Mab (NASDAQ:IMAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.

I-Mab has a consensus target price of $19.00, suggesting a potential upside of 1,087.50%. Given I-Mab's higher possible upside, analysts plainly believe I-Mab is more favorable than OvaScience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OvaScience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
I-Mab
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

I-Mab has a net margin of 0.00% compared to OvaScience's net margin of -10,128.37%. I-Mab's return on equity of 0.00% beat OvaScience's return on equity.

Company Net Margins Return on Equity Return on Assets
OvaScience-10,128.37% -47.06% -42.39%
I-Mab N/A N/A N/A

OvaScience received 222 more outperform votes than I-Mab when rated by MarketBeat users. Likewise, 63.87% of users gave OvaScience an outperform vote while only 61.18% of users gave I-Mab an outperform vote.

CompanyUnderperformOutperform
OvaScienceOutperform Votes
274
63.87%
Underperform Votes
155
36.13%
I-MabOutperform Votes
52
61.18%
Underperform Votes
33
38.82%

22.5% of OvaScience shares are owned by institutional investors. Comparatively, 22.6% of I-Mab shares are owned by institutional investors. 7.4% of OvaScience shares are owned by insiders. Comparatively, 22.1% of I-Mab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OvaScience has a beta of 3.11, indicating that its share price is 211% more volatile than the S&P 500. Comparatively, I-Mab has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.

OvaScience has higher earnings, but lower revenue than I-Mab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OvaScience$290K450.96-$50.97MN/AN/A
I-Mab$13.81M9.35-$363.53MN/AN/A

In the previous week, I-Mab had 1 more articles in the media than OvaScience. MarketBeat recorded 1 mentions for I-Mab and 0 mentions for OvaScience. OvaScience's average media sentiment score of 0.00 equaled I-Mab'saverage media sentiment score.

Company Overall Sentiment
OvaScience Neutral
I-Mab Neutral

Summary

I-Mab beats OvaScience on 9 of the 14 factors compared between the two stocks.


Get OvaScience News Delivered to You Automatically

Sign up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OVAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OVAS vs. The Competition

MetricOvaSciencePharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$130.78M$6.65B$4.97B$7.37B
Dividend YieldN/A2.74%2.91%3.86%
P/E RatioN/A9.2495.3014.70
Price / Sales450.96796.443,262.61154.77
Price / CashN/A18.3289.1453.45
Price / Book2.034.414.284.56
Net Income-$50.97M$156.18M$112.46M$207.29M

OvaScience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMAB
I-Mab
2.2043 of 5 stars
$1.64
-4.1%
$19.00
+1,058.5%
-63.8%$132.35M$13.81M0.00228
NGM
NGM Biopharmaceuticals
4.6946 of 5 stars
$1.61
+5.2%
$4.75
+195.0%
-56.9%$133.18M$55.33M-0.88239Upcoming Earnings
News Coverage
Positive News
MCRB
Seres Therapeutics
4.2599 of 5 stars
$1.04
-1.0%
$13.20
+1,169.2%
-79.0%$134.43M$7.13M-0.93431Gap Up
RENB
Renovaro Biosciences
0 of 5 stars
$2.02
-11.0%
N/AN/A$134.73MN/A-2.8912Gap Up
High Trading Volume
GBIO
Generation Bio
3.8245 of 5 stars
$1.97
-7.5%
$8.56
+334.4%
-54.2%$130.18MN/A-0.99150News Coverage
Gap Down
VTGN
Vistagen Therapeutics
1.6054 of 5 stars
$5.00
-2.0%
$19.00
+280.0%
-10.2%$135.10M$1.11M0.0033Positive News
ATOS
Atossa Therapeutics
1.0363 of 5 stars
$1.02
+1.0%
$4.50
+341.2%
+35.6%$127.81MN/A-4.2511
ORMP
Oramed Pharmaceuticals
0.2269 of 5 stars
$3.15
+0.3%
N/A+55.8%$127.07M$2.70M-7.6812News Coverage
High Trading Volume
NKTR
Nektar Therapeutics
3.6824 of 5 stars
$0.66
-7.0%
$3.00
+352.1%
-75.6%$126.60M$92.06M-0.43216Upcoming Earnings
Analyst Revision
Gap Up
KPTI
Karyopharm Therapeutics
3.6619 of 5 stars
$1.21
-4.7%
$6.00
+395.9%
-62.2%$138.58M$157.07M-0.92385Gap Down

Related Companies and Tools

This page (NASDAQ:OVAS) was last updated on 2/22/2024 by MarketBeat.com Staff